FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1862-1864 April 24, 2008 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Rader, D. J. Related Article by Barter, P. J. PubMed Citation

To the Editor: Barter et al. (Nov. 22 issue)¹ report the findings in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial of torcetrapib for the prevention of cardiovascular events. Was the result really as unexpected and its explanation as enigmatic as Rader suggests in his accompanying editorial?² Taking into account our knowledge about the function of cholesteryl ester transfer protein (CETP) and the fact that a heterozygous genetic CETP deficiency is associated with an increased prevalence of cardiovascular disease despite increased high-density lipoprotein (HDL) cholesterol,³ the answer is clearly no. Can the off-target . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.